Valuation dashboard for GeneDx Holdings Corp. (WGS) with P/E N/A, P/B 8.89, EV/EBITDA -29.92 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp.
Analysis Summary
GeneDx Holdings Corp. reported revenue of $427.5M in the most recent fiscal year, growing at a 5-year CAGR of 19.0%.
Trailing-twelve-month margins: gross margin 68.2%, operating margin -13.3%, net margin -23.4%.
At the current price of $76.27, WGS has negative trailing earnings (P/E not meaningful) and an ROE of -38.72%. Market capitalisation stands at $2.3B.
Balance sheet quality for WGS: current ratio of 2.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 8.89 |
| EV / EBITDA | -29.92 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-156.83 |
| vs Current Price | -305.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| WGS | GeneDx Holdings Corp. | $2.2B | 8.89 | -38.7% | |
| KYMR | Kymera Therapeutics, Inc. | $8.8B | 6.99 | -21.5% | |
| IMVT | Immunovant, Inc. | $6.9B | 9.40 | -69.6% | |
| OPCH | Option Care Health, Inc. | $3.4B | 17.02 | 2.78 | 15.7% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 7.52 | -46.9% | |
| NAMS | NewAmsterdam Pharma Company N.V. | $2.7B | 4.53 | -38.3% | |
| PRVA | Privia Health Group, Inc. | $2.5B | 90.26 | 0.00 | 0.0% |
| OSCR | Oscar Health, Inc. | $8.0B | 3.86 | -45.3% |
Price
| Price | $76.27 |
| Market Cap | $2.3B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -38.72% |
| Return on Invested Capital | -14.69% |
| Return on Assets | -22.09% |
| Gross Margin | 68.20% |
| Operating Margin | -13.34% |
| Net Margin | -23.40% |
Related companies: HNGE · IMVT · KYMR · NAMS · OPCH · OSCR
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of WGS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks